Arvinas

About:

Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.

Website: http://www.arvinas.com

Twitter/X: arvinasinc

Top Investors: RA Capital Management, OrbiMed, Deerfield, Connecticut Innovations, RTW Investments

Description:

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.

Total Funding Amount:

$462M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

New Haven, Connecticut, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)arvinas.com

Founders:

Craig M. Crews

Number of Employees:

251-500

Last Funding Date:

2023-11-27

IPO Status:

Public

© 2025 bioDAO.ai